4-(N-isopropylamino)benzoic acid | 121086-18-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(N-isopropylamino)benzoic acid
• 英文别名: N-isopropyl-p-aminobenzoic acid；4-isopropylamino-benzoic acid；4-Isopropylamino-benzoesaeure；Benzoic acid, 4-[(1-methylethyl)amino]-；4-(propan-2-ylamino)benzoic acid
• CAS: 121086-18-8
• 化学式: C₁₀H₁₃NO₂
• mdl: MFCD07370088
• 分子量: 179.219
• InChiKey: WGURDCUILNHQJP-UHFFFAOYSA-N

物化性质

• 熔点：
  150 °C(Solv: methanol (67-56-1))
• 沸点：
  333.8±25.0 °C(Predicted)
• 密度：
  1.157±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  ethyl 4-(isopropylamino)benzoate 生成 4-(N-isopropylamino)benzoic acid
  参考文献：
  名称：

  DE716668

  摘要：

  公开号：

文献信息

• [EN] HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES<br/>[FR] COMPOSÉS À PETITES MOLÉCULES MIMÉTIQUES DES FACTEURS DE CROISSANCE HÉMATOPOÏÉTIQUE ET LEURS UTILISATIONS
  申请人：LIGAND PHARM INC

  公开号：WO2011046954A1

  公开（公告）日：2011-04-21

  The present embodiments relate to compounds with physiological effects, such as the activation of hematopoietic growth factor receptors. The present embodiments also relate to use of the compounds to treat a variety of conditions, diseases and ailments such as hematopoietic conditions and disorders.

  目前的实施例涉及具有生理效应的化合物，例如激活造血生长因子受体。目前的实施例还涉及利用这些化合物来治疗各种疾病、疾病和疾患，如造血状况和疾病。
• POTENT ANALOGUES OF THE C-MYC INHIBITOR 10074-G5 WITH IMPROVED CELL PERMEABILITY
  申请人：University of Maryland, Baltimore

  公开号：US20140296307A1

  公开（公告）日：2014-10-02

  The present invention relates compounds and compositions for interfering with the association of Myc and Max. These compounds and compositions are useful in methods for inhibiting growth or proliferation of a cell. Methods of inhibiting growth or proliferation of a cell comprise contacting the cell with an amount of a compound that interferes with Myc and Max association effective to inhibit growth or proliferation of the cell. The compounds exhibit increased inhibitory activity against c-Myc relative to the known c-Myc inhibitor small-molecule benzofurazan N-([1,1′-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine (10074-G5).

  本发明涉及一种干扰Myc和Max结合的化合物和组合物。这些化合物和组合物在抑制细胞生长或增殖的方法中非常有用。抑制细胞生长或增殖的方法包括将干扰Myc和Max结合的化合物与细胞接触，有效地抑制细胞的生长或增殖。这些化合物对c-Myc表现出比已知的c-Myc抑制剂小分子苯并呋喃唑酮N-([1,1′-联苯基]-2-基)-7-硝基苯并[c][1,2,5]噁二唑-4-胺（10074-G5）更高的抑制活性。
• [EN] JAK AND HDAC DUAL-INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS DOUBLES DE JAK ET DE HDAC
  申请人：NAT UNIV SINGAPORE

  公开号：WO2017196261A1

  公开（公告）日：2017-11-16

  The present disclosure described provides novel dual inhibition compounds that specifically target the JAK-STAT and HDAC pathways, two distinct cellular pathways that are useful in the treatment of various diseases and disorders. In certain aspects, the compounds described herein are useful in the treatment of cellular proliferative and inflammatory diseases or disorders, such as graft vs. host disease. In particular embodiments, the compounds described herein inhibit JAK2 and HDAC6.

  本公开的描述提供了一种新颖的双重抑制化合物，专门针对JAK-STAT和HDAC途径，这两种不同的细胞途径对治疗各种疾病和障碍很有用。在某些方面，本文描述的化合物对细胞增殖性和炎症性疾病或障碍的治疗是有用的，例如移植物抗宿主病。在特定实施例中，本文描述的化合物抑制JAK2和HDAC6。
• Viral Polymerase Inhibitors
  申请人：Beaulieu Louis Pierre

  公开号：US20070142380A1

  公开（公告）日：2007-06-21

  An isomer, enantiomer, diastereoisomer or tautomer of a compound, represented by formula I: wherein A, B, R 2 , R 3 , L, M 1 , M 2 , M 3 , M 4 , Y 1 , Y 0 , Z and Sp are as defined in claim 1 , or a salt thereof, as an inhibitor of HCV NS5B polymerase.

  一种化合物的同分异构体、对映异构体、非对映异构体或互变异构体，其化学式为I：其中A、B、R2、R3、L、M1、M2、M3、M4、Y1、Y0、Z和Sp如权利要求1所定义，或其盐，作为HCV NS5B聚合酶的抑制剂。
• HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES
  申请人：Zhi Lin

  公开号：US20120295904A1

  公开（公告）日：2012-11-22

  The present embodiments relate to compounds with physiological effects, such as the activation of hematopoietic growth factor receptors. The present embodiments also relate to use of the compounds to treat a variety of conditions, diseases and ailments such as hematopoietic conditions and disorders.

  本实施例涉及具有生理效应的化合物，例如激活造血生长因子受体。本实施例还涉及使用这些化合物来治疗各种状况、疾病和疾病，例如造血系统状况和疾病。